NASDAQ:ANGO - AngioDynamics Stock Price, Forecast & News

AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO."

AngioDynamics, Inc. (NASDAQ:ANGO) issued its quarterly earnings results on Thursday, October, 3rd. The medical instruments supplier reported $0.08 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.04 by $0.04. The medical instruments supplier had revenue of $66 million for the quarter, compared to analysts' expectations of $67.74 million. AngioDynamics had a return on equity of 4.89% and a net margin of 17.79%. The firm's revenue for the quarter was up 3.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.16 EPS. View AngioDynamics' Earnings History.

AngioDynamics is scheduled to release their next quarterly earnings announcement on Friday, January 3rd 2020. View Earnings Estimates for AngioDynamics.

AngioDynamics updated its FY20 earnings guidance on Thursday, October, 3rd. The company provided earnings per share (EPS) guidance of $0.10-0.15 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.26. The company issued revenue guidance of $280-286 million, compared to the consensus revenue estimate of $281.89 million.

2 brokers have issued 1 year target prices for AngioDynamics' stock. Their forecasts range from $21.00 to $23.00. On average, they expect AngioDynamics' share price to reach $22.00 in the next year. This suggests a possible upside of 43.8% from the stock's current price. View Analyst Price Targets for AngioDynamics.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AngioDynamics.

News headlines about ANGO stock have been trending somewhat negative recently, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. AngioDynamics earned a news impact score of -1.7 on InfoTrie's scale. They also assigned news coverage about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for AngioDynamics.

AngioDynamics saw a decrease in short interest in November. As of November 15th, there was short interest totalling 748,500 shares, a decrease of 7.9% from the October 31st total of 812,500 shares. Based on an average daily volume of 267,200 shares, the short-interest ratio is currently 2.8 days. Currently, 2.0% of the company's stock are short sold. View AngioDynamics' Current Options Chain.

Some companies that are related to AngioDynamics include Medtronic (MDT), Abbott Laboratories (ABT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), ResMed (RMD), IDEXX Laboratories (IDXX), DexCom (DXCM), Teleflex (TFX), Hologic (HOLX), Steris (STE) and Varian Medical Systems (VAR).

Based on aggregate information from My MarketBeat watchlists, some companies that other AngioDynamics investors own include Oasis Petroleum (OAS), Intel (INTC), General Electric (GE), FireEye (FEYE), Mattel (MAT), Hanesbrands (HBI), Marathon Oil (MRO), Bank of America (BAC), Chesapeake Energy (CHK) and Centurylink (CTL).

AngioDynamics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include State Street Corp (3.69%), Tributary Capital Management LLC (1.80%), Fenimore Asset Management Inc. (1.52%), Granahan Investment Management Inc. MA (1.11%), Systematic Financial Management LP (1.09%) and Foundry Partners LLC (0.65%). Company insiders that own AngioDynamics stock include James C Clemmer, Kevin J Gould and Michael Greiner. View Institutional Ownership Trends for AngioDynamics.

ANGO stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Squarepoint Ops LLC, Man Group plc, Tributary Capital Management LLC, Barclays PLC, Foundry Partners LLC, State Street Corp and Keybank National Association OH. View Insider Buying and Selling for AngioDynamics.

ANGO stock was purchased by a variety of institutional investors in the last quarter, including State of New Jersey Common Pension Fund D, Mackay Shields LLC, Assenagon Asset Management S.A., Boston Advisors LLC, Systematic Financial Management LP, Granahan Investment Management Inc. MA, Tibra Equities Europe Ltd and Meeder Asset Management Inc.. View Insider Buying and Selling for AngioDynamics.

Shares of ANGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ANGO stock can currently be purchased for approximately $15.30.

AngioDynamics has a market capitalization of $575.59 million and generates $359.48 million in revenue each year. The medical instruments supplier earns $61.34 million in net income (profit) each year or $0.83 on an earnings per share basis. AngioDynamics employs 1,050 workers across the globe.View Additional Information About AngioDynamics.

The official website for AngioDynamics is http://www.angiodynamics.com/.

AngioDynamics' mailing address is 14 PLAZA DRIVE, LATHAM NY, 12110. The medical instruments supplier can be reached via phone at 518-795-1400 or via email at [email protected]